Trial results

AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

NCT07697391 on ClinicalTrials.gov · last registry update 2026-07-13

An unusually large phase 4: 285 participants, more than double the 72 typical for the stage. Due to report 31 October 2027, alongside 38 other tracked readouts that quarter. Primary outcome, as filed: Percent Change in Body Weight From Baseline to Week 52. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

NOT_YET_RECRUITING

Phase

P4

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

The First Affiliated Hospital of Anhui Medical University

Sponsor type

Other

Enrollment

285

Started

2026-07-20

Primary completion

2027-10-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change in Body Weight From Baseline to Week 52

Conditions studied

Obesity · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.